National Penn Investors Trust’s Ligand Pharmaceuticals LGND Stock Holding History

National Penn Investors Trust’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$304K	Buy	4,545 +1,018	+29%	+$61.9K	0.04%	170
2015 Q4	$239K	Buy	+3,527	New	+$218K	0.03%	193
2015 Q3	–	Sell	-3,342	Closed	-$210K	–	222
2015 Q2	$210K	Buy	+3,342	New	+$182K	0.02%	214

Other funds holding LGND

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

National Penn Investors Trust's LGND Position: Q1 2016 in Review

National Penn Investors Trust increased its Ligand Pharmaceuticals (LGND) stake by 29% in Q1 2016, buying an estimated $61.9K and bringing the position to 4,545 shares worth $304K. The position accounts for 0.04% of the portfolio, ranked #170.

National Penn Investors Trust first reported a position in LGND in Q2 2015 and has held it in 3 quarters since. 251 funds tracked by Wall St. Rank hold LGND as of Q1 2016.

National Penn Investors Trust held 4,545 shares of Ligand Pharmaceuticals worth $304K as of Q1 2016.
National Penn Investors Trust bought 1,018 Ligand Pharmaceuticals shares in Q1 2016, an estimated $61.9K.
Ligand Pharmaceuticals made up 0.04% of National Penn Investors Trust's portfolio in Q1 2016, its #170 holding.
National Penn Investors Trust first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 3 quarters since.
251 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2016.

Based on National Penn Investors Trust's 13F filing for Q1 2016, filed 11 May 2016.